Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reissue Patent
2001-04-06
2003-04-29
Myers, Carla J. (Department: 1634)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S099000, C514S601000
Reissue Patent
active
RE038103
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to compounds and pharmaceutical compositions for the treatment of inflammation, particularly cyclooxygenase mediated diseases and methods of treating thereof.
Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and inhibit hormone-induced uterine contractions and certain types of cancer growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase. Up until recently, only one form of cyclooxygenase had been characterized, this corresponding to cyclooxygenase-1 or the constitutive enzyme, as originally identified in bovine seminal vesicles. Recently the gene for an inducible form of cyclooxygenase (cyclooxygenase-2) has been cloned, sequenced and characterized from chicken, mu-rine and human sources. This enzyme is distinct from the cyclooxygenase-1 which has now also been cloned, sequenced and characterized from sheep, murine and human sources. The second form of cyclooxygenase, cyclooxygenase-2, is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. As prostaglandins have physiological and pathological roles, we have concluded that the constitutive enzyme, cyclooxygenase-1, is responsible, in large part, for endogenous basal release of prostaglandins and hence is important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow. In contrast, we have concluded that the inducible form, cyclooxygenase-2, is mainly responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as inflammatory agents, hormones, growth factors, and cytokines. Thus, a selective inhibitor of cyclooxygenase-2 will have similar antiinflammatory, antipyretic and analgesic properties of a conventional non-steroidal antiinflammatory drug (NSAID), and in addition would inhibit hormone-induced uterine contractions and have potential anti-cancer effects, but will have a diminished ability to induce some of the mechanism-based side effects. In particular, such a compound should have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.
SUMMARY OF THE INVENTION
The invention encompasses compounds of Formula I useful in the treatment of inflammation such as cyclooxygenase mediated diseases, particularly cyclooxygenase-2 mediated diseases.
The invention also encompasses methods of treating inflammation including cyclooxygenase mediated diseases, particularly cyclooxygenase-2 mediated diseases comprising: administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.
The invention also encompasses certain pharmaceutical compositions for treatment of inflammation including cyclooxygenase mediated diseases, particularly cyclooxygenase-2 mediated diseases comprising compounds of Formula I and a pharmaceutically acceptable carrier.
The invention also encompasses the compound 12
and pharmaceutically acceptable salts thereof which are useful in the treatment of inflammation such as cyclooxygenase mediated diseases, in particular cyclooxygenase-2 mediated diseases.
The invention also encompasses anti-inflammatory pharmaceutical compositions such as those useful for inhibiting a cyclooxygenase and for treating cyclooxygenase mediated diseases as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of the compound of Formula I as described herein.
The pharmaceutical compositions of the present invention comprise a compound of Formulas I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases including s inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium sodium, zinc and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from o pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline,-N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylgncamine, morpholine, piperazine, piperdine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
The invention also encompasses methods of inhibiting cyclooxygenase and treating cyclooxygenase mediated diseases comprising: administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of compound of Formula I as disclosed herein.
It will be understood that in the discussion of methods of treatment which follows, references to the compound of Formula I are meant to also include the pharmaceutically acceptable salts.
REFERENCES:
patent: 2646385 (1953-07-01), Lewenstein
patent: 3010873 (1961-11-01), Cavallini et al.
patent: 3121044 (1964-02-01), Buckwalter et al.
patent: 3128226 (1964-04-01), Rubin et al.
patent: 3439009 (1969-04-01), Emele
patent: 3840597 (1974-10-01), Moore et al.
patent: 4244960 (1981-01-01), Schroeder et al.
patent: 4375479 (1983-03-01), Schroeder et al.
patent: 4820827 (1989-04-01), Haber
patent: 4866091 (1989-09-01), Matsuo et al.
patent: 4885367 (1989-12-01), Yoshikawa et al.
patent: 5409944 (1995-04-01), Black et al.
patent: 130870/86 (1986-01-01), None
patent: 242997/90 (1992-04-01), None
Boyce et al. Nueropharmacology. 1994. vol. 33, No. 12, pp. 1609-1611.*
Wisenberg-Bottcher et al. Agents and Actions. 1989. vol. 26, pp. 240-242.*
Lombardino et al. Arzneim.-Forsch. (Drug Res.) 1975. vol. 25, No. 10, pp. 1629-1635.*
Lombardino. Nonsteroidal Antiinflammatory Drugs. 1985. pp. 114-130.*
National Meeting of the American Chemical Society, Washington, D.C., USA, Aug. 21-25, 1994. Abstracts of Papers American Chemical Society. 208 (1-2), 1994 MEDI 272, ISSN: 0065-7727.*
National Meeting of the American Chemical Society, Washington, D.C., USA, Aug. 21-25, 1994. Abstracts of Papers American Chemical Society. 208 (1-2), 1994 MEDI 116, ISSN: 0065-7727.*
Chem Abstracts. 1983. vol. 100, No. 1, AB #6113u.*
D.P. Carr, et al., Agents and Actions, vol. 19, 5/6 (1986) pp. 374-375, “Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastro-intestinal toxicity . . .”.*
Chem Abstracts. 1985. vol. 104, AB #107904r.*
Chem Abstracts. 1990. vol. 113, AB #224303r.*
Chem Abstracts. 1987. vol. 106, AB #60922u.*
Chem Abstracts. 1989. vol. 110, AB #128249v.*
Gans et al. Journal of Pharm. and Experim. Ther., 1990. vol. 254, No. 1, pp. 180-187.*
Hla et al. Proceedings of the National Academy of Sciences, USA. 1992. vol. 89, pp. 7384-7388.*
Rufer et al. European Journal of Med. Chem. Chim. Ther. 1982. vol. 17, pp. 173-180.
Guay Daniel
Li Chun-Sing
Howrey Simon Arnold & White , LLP
Merck Frosst Canada & Co.
Myers Carla J.
LandOfFree
5-methanesulfonamido-1-indanones as an inhibitor of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-methanesulfonamido-1-indanones as an inhibitor of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-methanesulfonamido-1-indanones as an inhibitor of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3013196